PortalPublikationenAdjuvant radiotherapy and local recurrence in vulvar cancer ...

Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study

Standard

Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study. / Woelber, Linn; Prieske, Katharina; Eulenburg, Christine Zu; Corradini, Stefanie; Petersen, Cordula; Bommert, Mareike; Blankenstein, Thomas; Hilpert, Felix; de Gregorio, Nikolaus; Iborra, Severine; Sehouli, Jalid; Ignatov, Atanas; Hillemanns, Peter; Fuerst, Sophie; Strauss, Hans-Georg; Baumann, Klaus; Beckmann, Matthias W; Mustea, Alexander; Mahner, Sven; Jaeger, Anna.

in: GYNECOL ONCOL, Jahrgang 164, Nr. 1, 01.2022, S. 68-75.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Woelber, L, Prieske, K, Eulenburg, CZ, Corradini, S, Petersen, C, Bommert, M, Blankenstein, T, Hilpert, F, de Gregorio, N, Iborra, S, Sehouli, J, Ignatov, A, Hillemanns, P, Fuerst, S, Strauss, H-G, Baumann, K, Beckmann, MW, Mustea, A, Mahner, S & Jaeger, A 2022, 'Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study', GYNECOL ONCOL, Jg. 164, Nr. 1, S. 68-75. https://doi.org/10.1016/j.ygyno.2021.11.004

APA

Woelber, L., Prieske, K., Eulenburg, C. Z., Corradini, S., Petersen, C., Bommert, M., Blankenstein, T., Hilpert, F., de Gregorio, N., Iborra, S., Sehouli, J., Ignatov, A., Hillemanns, P., Fuerst, S., Strauss, H-G., Baumann, K., Beckmann, M. W., Mustea, A., Mahner, S., & Jaeger, A. (2022). Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study. GYNECOL ONCOL, 164(1), 68-75. https://doi.org/10.1016/j.ygyno.2021.11.004

Vancouver

Woelber L, Prieske K, Eulenburg CZ, Corradini S, Petersen C, Bommert M et al. Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study. GYNECOL ONCOL. 2022 Jan;164(1):68-75. https://doi.org/10.1016/j.ygyno.2021.11.004

Bibtex

@article{e342ec0339a04c578faae002b99e909f,
title = "Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study",
abstract = "BACKGROUND: The impact of adjuvant radiotherapy (RT) to the vulva with regard to prognosis and local recurrence in patients with vulvar squamous cell cancer (VSCC) is poorly described.PATIENTS AND METHODS: In the AGO-CaRE-1 study 1618 patients with primary VSCC FIGO stage ≥ IB, treated between 1998-2008, were documented. In this retrospective subanalysis, 360 patients were included based on the following criteria: nodal involvement (pN+), known RT treatment and known radiation fields.RESULTS: The majority had pT1b/pT2 tumors (n=299; 83.1%). In 76.7%, R0 resection was achieved. 57/360 (15.8%) N+ patients were treated with adjuvant RT to the groins/pelvis and 146/360 (40.5%) received adjuvant RT to the vulva and groins/pelvis. 157/360 (43.6%) patients did not receive any adjuvant RT. HPV status was available in 162/360 patients (45.0%), 75/162 tumors were HPV+(46.3%), 87/162 (53.7%) HPV-. During a median follow-up of 17.2 months, recurrence at the vulva only occurred in 25.5% of patients without adjuvant RT, in 22.8% of patients with adjuvant RT to groins/pelvis and in 15.8% of patients with adjuvant RT to the vulva and groins/pelvis respectively. The risk reducing effect of local RT was independent of the resection margin status. 50% disease free survival time (50% DFST) indicated a stronger impact of adjuvant RT to the vulva in HPV+ compared to HPV- patients (50% DFST 20.7 months vs. 17.8 months).CONCLUSION: Adjuvant RT to the vulva was associated with a lower risk for local recurrence in N+ VSCC independent of the resection margin status. This observation was more pronounced in patients with HPV+ tumors in comparison to HPV- tumors.",
author = "Linn Woelber and Katharina Prieske and Eulenburg, {Christine Zu} and Stefanie Corradini and Cordula Petersen and Mareike Bommert and Thomas Blankenstein and Felix Hilpert and {de Gregorio}, Nikolaus and Severine Iborra and Jalid Sehouli and Atanas Ignatov and Peter Hillemanns and Sophie Fuerst and Hans-Georg Strauss and Klaus Baumann and Beckmann, {Matthias W} and Alexander Mustea and Sven Mahner and Anna Jaeger",
note = "Copyright {\textcopyright} 2021 The Author(s). Published by Elsevier Inc. All rights reserved.",
year = "2022",
month = jan,
doi = "10.1016/j.ygyno.2021.11.004",
language = "English",
volume = "164",
pages = "68--75",
journal = "GYNECOL ONCOL",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

RIS

TY - JOUR

T1 - Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study

AU - Woelber, Linn

AU - Prieske, Katharina

AU - Eulenburg, Christine Zu

AU - Corradini, Stefanie

AU - Petersen, Cordula

AU - Bommert, Mareike

AU - Blankenstein, Thomas

AU - Hilpert, Felix

AU - de Gregorio, Nikolaus

AU - Iborra, Severine

AU - Sehouli, Jalid

AU - Ignatov, Atanas

AU - Hillemanns, Peter

AU - Fuerst, Sophie

AU - Strauss, Hans-Georg

AU - Baumann, Klaus

AU - Beckmann, Matthias W

AU - Mustea, Alexander

AU - Mahner, Sven

AU - Jaeger, Anna

N1 - Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

PY - 2022/1

Y1 - 2022/1

N2 - BACKGROUND: The impact of adjuvant radiotherapy (RT) to the vulva with regard to prognosis and local recurrence in patients with vulvar squamous cell cancer (VSCC) is poorly described.PATIENTS AND METHODS: In the AGO-CaRE-1 study 1618 patients with primary VSCC FIGO stage ≥ IB, treated between 1998-2008, were documented. In this retrospective subanalysis, 360 patients were included based on the following criteria: nodal involvement (pN+), known RT treatment and known radiation fields.RESULTS: The majority had pT1b/pT2 tumors (n=299; 83.1%). In 76.7%, R0 resection was achieved. 57/360 (15.8%) N+ patients were treated with adjuvant RT to the groins/pelvis and 146/360 (40.5%) received adjuvant RT to the vulva and groins/pelvis. 157/360 (43.6%) patients did not receive any adjuvant RT. HPV status was available in 162/360 patients (45.0%), 75/162 tumors were HPV+(46.3%), 87/162 (53.7%) HPV-. During a median follow-up of 17.2 months, recurrence at the vulva only occurred in 25.5% of patients without adjuvant RT, in 22.8% of patients with adjuvant RT to groins/pelvis and in 15.8% of patients with adjuvant RT to the vulva and groins/pelvis respectively. The risk reducing effect of local RT was independent of the resection margin status. 50% disease free survival time (50% DFST) indicated a stronger impact of adjuvant RT to the vulva in HPV+ compared to HPV- patients (50% DFST 20.7 months vs. 17.8 months).CONCLUSION: Adjuvant RT to the vulva was associated with a lower risk for local recurrence in N+ VSCC independent of the resection margin status. This observation was more pronounced in patients with HPV+ tumors in comparison to HPV- tumors.

AB - BACKGROUND: The impact of adjuvant radiotherapy (RT) to the vulva with regard to prognosis and local recurrence in patients with vulvar squamous cell cancer (VSCC) is poorly described.PATIENTS AND METHODS: In the AGO-CaRE-1 study 1618 patients with primary VSCC FIGO stage ≥ IB, treated between 1998-2008, were documented. In this retrospective subanalysis, 360 patients were included based on the following criteria: nodal involvement (pN+), known RT treatment and known radiation fields.RESULTS: The majority had pT1b/pT2 tumors (n=299; 83.1%). In 76.7%, R0 resection was achieved. 57/360 (15.8%) N+ patients were treated with adjuvant RT to the groins/pelvis and 146/360 (40.5%) received adjuvant RT to the vulva and groins/pelvis. 157/360 (43.6%) patients did not receive any adjuvant RT. HPV status was available in 162/360 patients (45.0%), 75/162 tumors were HPV+(46.3%), 87/162 (53.7%) HPV-. During a median follow-up of 17.2 months, recurrence at the vulva only occurred in 25.5% of patients without adjuvant RT, in 22.8% of patients with adjuvant RT to groins/pelvis and in 15.8% of patients with adjuvant RT to the vulva and groins/pelvis respectively. The risk reducing effect of local RT was independent of the resection margin status. 50% disease free survival time (50% DFST) indicated a stronger impact of adjuvant RT to the vulva in HPV+ compared to HPV- patients (50% DFST 20.7 months vs. 17.8 months).CONCLUSION: Adjuvant RT to the vulva was associated with a lower risk for local recurrence in N+ VSCC independent of the resection margin status. This observation was more pronounced in patients with HPV+ tumors in comparison to HPV- tumors.

U2 - 10.1016/j.ygyno.2021.11.004

DO - 10.1016/j.ygyno.2021.11.004

M3 - SCORING: Journal article

C2 - 34794839

VL - 164

SP - 68

EP - 75

JO - GYNECOL ONCOL

JF - GYNECOL ONCOL

SN - 0090-8258

IS - 1

ER -